Skip to main content

View full-text article in PMC

. 2020 Aug 13;124:103967. doi: 10.1016/j.compbiomed.2020.103967

Table 4.

Analysis of the population coverage using potential MHC I and MHC II interacted alleles for the proposed multi-epitope vaccine against SARS-CoV-2.

Population/Area	MHC I Combined			MHC II Combined
Population/Area	Coverage (%)^a	Average hit^b	PC90^c	Coverage (%)^a	Average hit^b	PC90^c
Central Africa	63.97	1.56	0.28	46.24	1.12	0.19
Central America	2.19	0.04	0.10	23.76	0.43	0.13
East Africa	60.78	1.40	0.25	51.00	1.51	0.20
East Asia	62.39	1.49	0.27	57.95	1.65	0.24
Europe	77.91	1.86	0.45	65.71	2.16	0.29
North Africa	72.00	1.77	0.36	57.03	1.15	0.23
North America	65.50	1.59	0.29	63.77	2.01	0.28
Northeast Asia	56.06	1.54	0.23	36.94	0.77	0.16
Oceania	35.97	0.67	0.16	43.67	0.94	0.18
South Africa	70.08	1.71	0.33	5.91	0.12	0.21
South America	46.65	0.91	0.19	26.99	0.71	0.14
South Asia	69.11	1.53	0.32	60.68	1.63	0.25
Southeast Asia	44.14	1.08	0.18	35.62	0.67	0.16
Southwest Asia	60.13	1.14	0.25	31.97	0.76	0.15
West Africa	77.98	2.17	0.45	47.72	1.25	0.19
West Indies	56.56	1.22	0.23	54.15	1.72	0.22

^a

Projected population coverage.

^b

Average number of epitope hits/HLA combinations recognized by the population.

^c

Minimum number of epitope hits/HLA combinations recognized by 90% of the population.